Technical analysis of NuCana plc (NCNA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform.
Price Performance
| 1 month | -14.47% |
| 3 months | -31.94% |
| Year-to-date | -63.89% |
| 1 year | -67.17% |
| 3 years | -99.96% |
| 5 years | -99.99% |
52-Week Range
| 52-week High | $7.22 |
| 52-week Low | $1.21 |
| Avg Volume (90d) | 59K |
Technical Indicators
| SMA 50 | $1.39 |
| SMA 200 | $2.16 |
| Beta | 1.80 |
| 30-day Volatility (annualised) | 87.8% |
| Price vs SMA 50 | -6.5% |
| Price vs SMA 200 | -39.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $4.01 | |
| 2025-11 | $4.28 | +6.7% |
| 2025-12 | $3.60 | -15.9% |
| 2026-01 | $2.51 | -30.3% |
| 2026-02 | $2.16 | -13.9% |
| 2026-03 | $1.40 | -35.2% |
| 2026-04 | $2.13 | +52.1% |
| 2026-05 | $2.33 | +9.4% |
| 2026-06 | $1.52 | -34.8% |
| 2026-07 | $1.32 | -13.2% |
| 2026-08 | $1.47 | +11.4% |
| 2026-09 | $1.30 | -11.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.30 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 0.23 |
| EV / EBITDA | 0.85 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 5.60 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -12.10 |